Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Brazikumab in Healthy Chinese and White Participants
NCT05033431Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of brazikumab in Crohn's disease and ulcerative colitis (UC) (6 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed serum (peak) drug concentration, Area under serum concentration-time curve from zero to infinity and 2 more. Started Oct 2021; status: completed.
02
Drugs
brazikumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05033431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033431.